Compare FINV & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | COLL |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | FINV | COLL |
|---|---|---|
| Price | $4.96 | $46.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $11.55 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 1.0M | 481.4K |
| Earning Date | 11-19-2025 | 02-26-2026 |
| Dividend Yield | ★ 5.59% | N/A |
| EPS Growth | ★ 27.76 | N/A |
| EPS | 1.50 | ★ 1.63 |
| Revenue | ★ $1,969,555,571.00 | $757,067,000.00 |
| Revenue This Year | $6.02 | $26.35 |
| Revenue Next Year | N/A | $3.67 |
| P/E Ratio | ★ $3.45 | $30.01 |
| Revenue Growth | 8.81 | ★ 26.34 |
| 52 Week Low | $4.70 | $23.23 |
| 52 Week High | $11.08 | $50.79 |
| Indicator | FINV | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 38.33 | 46.23 |
| Support Level | $5.17 | $44.51 |
| Resistance Level | $5.49 | $49.17 |
| Average True Range (ATR) | 0.21 | 1.65 |
| MACD | 0.00 | -0.41 |
| Stochastic Oscillator | 3.03 | 26.77 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.